دورية أكاديمية
Restrictive measure for the commercialization of antimicrobials in Brazil: results achieved.
| العنوان: | Restrictive measure for the commercialization of antimicrobials in Brazil: results achieved. |
|---|---|
| المؤلفون: | Costa JMD; Universidade Federal de Minas Gerais. Faculdade de Farmácia. Programa de Pós-Graduação em Medicamentos e Assistência Farmacêutica. Belo Horizonte, MG, Brasil., Moura CS; McGill University. Division of Clinical Epidemiology. Department of Epidemiology. Montreal, Quebec, Canada., Pádua CAM; Universidade Federal de Minas Gerais. Faculdade de Farmácia. Departamento de Farmácia Social. Belo Horizonte, MG, Brasil., Vegi ASF; McGill University. Division of Clinical Epidemiology. Department of Epidemiology. Montreal, Quebec, Canada., Magalhães SMS; Universidade Federal de Minas Gerais. Faculdade de Farmácia. Departamento de Farmácia Social. Belo Horizonte, MG, Brasil., Rodrigues MB; Universidade Federal de Minas Gerais. Faculdade de Farmácia. Departamento de Farmácia Social. Belo Horizonte, MG, Brasil., Ribeiro AQ; Universidade Federal de Viçosa. Centro de Ciências Biológicas e da Saúde. Departamento de Nutrição e Saúde. Viçosa, MG, Brasil. |
| المصدر: | Revista de saude publica [Rev Saude Publica] 2019 Aug 19; Vol. 53, pp. 68. Date of Electronic Publication: 2019 Aug 19. |
| نوع المنشور: | Journal Article |
| اللغة: | English; Portuguese |
| بيانات الدورية: | Publisher: Universidade De Sao Paulo. Faculdade De Higiene E Saude Publica Country of Publication: Brazil NLM ID: 0135043 Publication Model: Electronic Cited Medium: Internet ISSN: 1518-8787 (Electronic) Linking ISSN: 00348910 NLM ISO Abbreviation: Rev Saude Publica Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Sao Paulo : Universidade De Sao Paulo. Faculdade De Higiene E Saude Publica |
| مواضيع طبية MeSH: | Drug Resistance, Microbial*, Anti-Bacterial Agents/*administration & dosage , Cross Infection/*drug therapy , Cross Infection/*prevention & control , Prescription Drug Overuse/*legislation & jurisprudence, Brazil ; Cohort Studies ; Drug Monitoring ; Drug Utilization/legislation & jurisprudence ; Female ; Humans ; Infection Control/methods ; Male ; Middle Aged ; Prescription Drug Overuse/adverse effects ; Prescription Drug Overuse/statistics & numerical data ; beta-Lactamases/drug effects |
| مستخلص: | Objective: To assess whether the incidence of hospital infection by a resistant microorganism decreased after the implementation of the restrictive measure of the National Health Surveillance Agency for the commercialization of antimicrobials. Methods: A historical cohort study of medical records of adult patients admitted to a general and public hospital from May 2010 to July 2011. A cohort was formed with patients admitted in the period before the restrictive measure for the commercialization of antimicrobials (Phase I) and a second cohort was formed with patients admitted after the implementation of the restrictive measure (Phase II). Results: The instantaneous risk of hospital infection by a resistant microorganism was estimated at seven by 1,000 people-time (95%CI 0.006-0.008) in Phase I, and four by 1,000 people-time (95%CI 0.003-0.005) in Phase II of the study. The differences between the survival curves in the different phases of the study and stratified by age group were also significant (p < 0.05). Conclusions: The results suggest that the implementation of the restrictive measure of the commercialization of antimicrobials by the National Health Surveillance Agency reduced the incidence of hospital infection by a resistant microorganism. |
| References: | Lancet Infect Dis. 2014 Aug;14(8):742-750. (PMID: 25022435) J Glob Antimicrob Resist. 2017 Sep;10:195-199. (PMID: 28735057) Antimicrob Resist Infect Control. 2018 May 2;7:63. (PMID: 29744044) Ceylon Med J. 2016 Sept;61(3):113-117. (PMID: 27727410) Lancet Infect Dis. 2015 Dec;15(12):1438-49. (PMID: 26411518) J Antimicrob Chemother. 2008 Nov;62 Suppl 2:ii105-14. (PMID: 18819975) New Microbes New Infect. 2015 Apr 16;6:22-9. (PMID: 26029375) BMJ. 2016 Mar 15;352:i939. (PMID: 26980184) J Clin Microbiol. 2018 Oct 25;56(11):. (PMID: 30158194) Cien Saude Colet. 2008 Apr;13 Suppl:711-20. (PMID: 21936176) Int J Antimicrob Agents. 2016 Jul;48(1):27-32. (PMID: 27318624) J Microbiol. 2011 Feb;49(1):46-52. (PMID: 21369978) Antimicrob Agents Chemother. 2013 Sep;57(9):4410-6. (PMID: 23817383) Medicine (Baltimore). 2015 Sep;94(38):e1605. (PMID: 26402824) Braz J Infect Dis. 2010 Jan-Feb;14(1):71-6. (PMID: 20428658) PLoS One. 2018 Sep 11;13(9):e0203641. (PMID: 30204782) Ann Intern Med. 2015 Sep 1;163(5):386-8. (PMID: 26167660) J Clin Pharm Ther. 2016 Oct;41(5):532-7. (PMID: 27511808) Rev Soc Bras Med Trop. 2010 Jan-Feb;43(1):68-72. (PMID: 20305972) Drug Discov Today Technol. 2014 Mar;11:33-9. (PMID: 24847651) CMAJ. 2012 Jan 10;184(1):37-42. (PMID: 22143235) |
| المشرفين على المادة: | 0 (Anti-Bacterial Agents) EC 3.5.2.6 (beta-Lactamases) |
| تواريخ الأحداث: | Date Created: 20190822 Date Completed: 20190909 Latest Revision: 20240719 |
| رمز التحديث: | 20240719 |
| مُعرف محوري في PubMed: | PMC6705550 |
| DOI: | 10.11606/s1518-8787.2019053000879 |
| PMID: | 31432930 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1518-8787 |
|---|---|
| DOI: | 10.11606/s1518-8787.2019053000879 |